News
Analysts have set 12-month price targets for Neurocrine Biosciences, revealing an average target of $155.06, a high estimate of $182.00, and a low estimate of $115.00. This current average reflects an ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance.
ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) (“Supernus”) today announced that it has successfully completed its previously announced acquisition of ...
Neurocrine Biosciences continues strong with Ingrezza and Crenessity growth, plus a promising pipeline in MDD and ...
Serina Therapeutics advances POZ-VMAT2i into development for tardive dyskinesia: Huntsville, Alabama Thursday, July 31, 2025, 14:00 Hrs [IST] Serina Therapeutics, Inc. (Serina), a ...
1d
Investor's Business Daily on MSNWhy Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 EarningsGeneric drugs had a "stable" performance in the second quarter, with global revenue down about 2% in local currency.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a ...
The majority of Teva's business lies in generic and off-patent branded drugs which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best strong buy healthcare stocks to buy now. On July 22, Morgan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results